STAT+: Pharmalittle: Novartis to help make CureVac Covid-19 vaccine; U.K. to speed vaccine approvals for Covid-19 variants
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
Category: STAT+
STAT+: Kronos Bio speeds development of genetically targeted leukemia drug with unique trial design
Kronos Bio said Thursday that it had reached an agreement with the Food and Drug…
STAT+: Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial
Eli Lilly said Thursday that a study showed its experimental diabetes drug, tirzepatide, reduced patients’…
STAT+: FDA releases a new plan to bring its data skills up to speed
When Ram Iyer started his new job at the Food and Drug Administration in 2020,…
STAT+: Health care industry scores lobbying wins in Senate on drug pricing, provider funds, insurance subsidies
WASHINGTON — Health care industry lobbying groups are poised to score big wins in the…
.jpg)
STAT+: South Africa official explains why world trade rules should be waived to fight Covid-19
Last fall, the governments of India and South Africa asked the World Trade Organization to…
STAT+: Pharmalittle: A race is on to find alternatives to syringes and needles for vaccines; FDA under pressure to inspect more plants
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Ovid sells off its lead drug to double down on neuro research
Ovid Therapeutics, months removed from a crushing clinical trial disappointment, said Wednesday that it is…
STAT+: Apple Watch research plows ahead, revealing the device’s health potential
Apple has marketed its Watch for years as a tool to monitor and improve your…
STAT+: Amazon Care’s health provider has quietly filed paperwork to operate in 17 more states
The clinical provider for Amazon Care, the tech giant’s virtual-first medical platform, is quietly gearing…
STAT+: Pharmalittle: Merck will help J&J make its Covid-19 vaccine; Trump used hospital funds to bankroll Warp Speed
Rise and shine, another busy day is on the way. We can tell because our…
Opinion: STAT+: Create a U.S. Institute of Health Technology Assessment to preserve innovation and control costs
The public outcry to “do something” about health care spending keeps growing, but fear about…
STAT+: 5 names to know: the key players steering Amazon’s sprawling push into health care
Its spinout Haven may have shuttered, but Amazon’s appetite for health care disruption has only…
STAT+: A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill
Fibrogen was expecting the Food and Drug Administration to complete a review of its experimental…
STAT+: A nascent state effort would tax drug makers for not providing clinical evidence for price hikes
In a bid to control the cost of medicines, lawmakers in two states — Hawaii…
STAT+: New Mexico attorney general accuses Gilead of blocking competition to its HIV medicines
The New Mexico attorney general has filed a lawsuit against Gilead Sciences (GILD) and two…
STAT+: Pharmalittle: J&J Covid-19 vaccine supply will be uneven; pandemic ushers in a ‘golden age of vaccinology’
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Janet Woodcock revolutionized the way the FDA reviews cancer drugs, inspiring her supporters and raising concerns for detractors
WASHINGTON — In 2000, the Food and Drug Administration approved just three cancer drugs. Last…
STAT+: Cigna’s Evernorth to acquire telehealth company MDLive
Riding a wave of pandemic-fueled momentum for virtual care, Cigna subsidiary Evernorth is acquiring telehealth…
STAT+: Pharmalittle: Sarepta wins another FDA nod; Germans balk at AstraZeneca vaccine
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT+: Sen. Cassidy explains why he’s backing a bill aimed at drug-resistant bacteria
The Covid-19 pandemic has shown the damage that an uncontrolled infectious disease can cause society….
STAT+: The vial is not half empty: New report lays out ways to address the issue of discarded drugs
File this under ‘Waste not, want not.’ In response to the cost of medicines, a…
STAT+: Pharmalittle: Moderna proceeds with a vaccine trial to combat Covid-19 variant; who will be the next FDA commish?
Top of the morning to you, and a fine one it is. Once again, clear…
STAT+: A U.S. court ruling may force biologics makers to review patent protections
In a decision with broad implications for the pharmaceutical industry, a U.S. appeals court recently…
STAT+: CytoDyn has data on its highly touted experimental Covid treatment. Investors and patients don’t
CytoDyn CEO Nader Pourhassan has been uncharacteristically quiet this week about a completed clinical trial…
STAT+: Once again, the credit outlook for the pharmaceutical industry is negative
For the eighth consecutive year, the credit outlook for the pharmaceutical industry is negative and…
STAT+: ‘It looks like a spaghetti bowl’: Scientists reveal a precise structure in a fabled worm’s tangled brain
Using Facebook-like algorithms, a bespoke microscope, and hefty doses of patience, a team of scientists…
STAT+: Pharmalittle: FDA scientists say J&J Covid-19 shot is effective; vaccine makers predict big jump in deliveries this month
Good morning, everyone, and how are you today? We are doing just fine, thanks to…
STAT+: With genome-editing companies’ stock booming, Beam Therapeutics seizes its moment
Beam Therapeutics, a company focused on genome editing, is in a strange situation. The firm’s…
STAT+: Access to heart drugs improves in middle-income countries, but still lags compared to wealthy nations
Middle-income countries have gained greater access to a variety of needed cardiovascular medicines, but remain…
STAT+: STAT+ Conversations: A conversation with a leading biotech venture capitalist
Editors Note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: Pfizer accused of ‘bullying’ some countries during vaccine talks; FDA to quickly analyze Covid-19 booster shots
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Google reveals new progress on controversial project using patient data
More than a year after facing widespread criticism over its patient data-sharing arrangement with hospital…
STAT+: The questions Congress should ask Pfizer, Moderna, and Johnson & Johnson about the Covid-19 vaccines
WASHINGTON — Executives from Pfizer, Moderna, Johnson & Johnson, AstraZeneca, and Novavax will testify Tuesday…
STAT+: ‘Following the Amazon playbook’: As digital pharmacy grows more crowded, startups scramble to stand out
Ever since Amazon launched its digital pharmacy late last year, industry rivals have been worried…
STAT+: Pharmalittle: Glaxo and Sanofi start new trial of Covid-19 vaccine; AstraZeneca ends a drug’s use for bladder cancer after failed trial
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes
The Food and Drug Administration told Brainstorm Therapeutics that rejiggered data from a negative clinical…
STAT+: AbbVie smooths over a dispute about alleged theft of trade secrets for a new version of Botox
After two years of bickering, AbbVie (ABBV) and a marketing partner have settled a dispute…
STAT+: Federal watchdog raises concerns about increasing telehealth fraud during pandemic
WASHINGTON — A federal government watchdog is sounding the alarm that Americans’ growing enthusiasm for…
STAT+: Pharmalittle: Single Pfizer shot is 85% effective in preventing symptomatic Covid-19; Biden to commit $4 billion to COVAX
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Federal judge nixes hospitals’ attempt to force HHS 340B crackdown
WASHINGTON — A federal judge ruled Thursday that it’s too early for hospitals to challenge…
Pharmalittle: Pfizer vaccine seems less potent against Covid-19 variant in lab test; WTO urges end to vaccine export restrictions
Hello, everyone, and how are you today? We are doing just dandy, despite another blanket…
STAT+: Covid crushed in-person pharma sales. Tech is pitching itself as a solution
The pandemic grounded tens of thousands of pharmaceutical reps who usually roam the country urging…
STAT+: States still can’t import drugs from Canada. Now, many are seeking to import Canadian prices
WASHINGTON — For years, former President Trump threatened to use foreign prices as a cap…
STAT+: Pharmalittle: First Covid-19 human challenge study to begin; vaccine firm executives profit from insider stock sales
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Cancer cases place Bluebird Bio’s gene therapy business at a crossroads, and might drag the entire field along
Bluebird Bio’s disclosure Tuesday that two additional patients being treated with its gene therapy for…
STAT+: Backed by big hospitals, a former Microsoft executive wades into the messy business of selling patient data
He was once dubbed “the most important man at Microsoft,” a prodigiously talented software engineer…
STAT+: FDA warns AcelRx of misleading ads for its pain drug Dsuvia
The manufacturer of Dsuvia, a pain drug approved by the Food and Drug Administration amid…
STAT+: After a controversial Alzheimer’s drug review, FDA’s Woodcock rejects proposal to ‘firewall’ agency and drug companies
In response to criticism, a top Food and Drug Administration official maintained that creating a…
STAT+: Pharmalittle: WHO approves AstraZeneca Covid-19 vaccine; North Korean hackers target Pfizer vaccine data
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…